Novo Nordisk’s Wegovy Approved in UK for Reducing Cardiovascular Risk in Obese Adults

Novo Nordisk recently announced that its weight-loss drug, Wegovy, has been approved by UK regulatory authorities for use in reducing cardiovascular problems and stroke risk in overweight and obese adults.

The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) stated that this approval is similar to the approval the US Food and Drug Administration (FDA) granted in March.

With this decision, Wegovy became the first GLP-1 medication to be prescribed for the prevention of cardiovascular diseases in obese patients.

Meanwhile, according to the British Heart Foundation, more than 7.6 million people in the UK suffer from cardiovascular disease each year.

The FDA’s approval was based on clinical trials showing that Wegovy reduced the risk of major cardiovascular events, such as heart attacks and strokes, by 20% compared to a placebo.